S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.87 (-2.41%)
MSFT   283.20 (-3.73%)
FB   340.65 (-3.66%)
GOOGL   2,716.90 (-3.71%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   205.89 (-4.94%)
BABA   152.11 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.74 (-5.91%)
AMD   100.87 (-6.74%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.06 (-1.17%)
BA   218.41 (-2.57%)
AMC   36.68 (-6.67%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.87 (-2.41%)
MSFT   283.20 (-3.73%)
FB   340.65 (-3.66%)
GOOGL   2,716.90 (-3.71%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   205.89 (-4.94%)
BABA   152.11 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.74 (-5.91%)
AMD   100.87 (-6.74%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.06 (-1.17%)
BA   218.41 (-2.57%)
AMC   36.68 (-6.67%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.87 (-2.41%)
MSFT   283.20 (-3.73%)
FB   340.65 (-3.66%)
GOOGL   2,716.90 (-3.71%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   205.89 (-4.94%)
BABA   152.11 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.74 (-5.91%)
AMD   100.87 (-6.74%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.06 (-1.17%)
BA   218.41 (-2.57%)
AMC   36.68 (-6.67%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.87 (-2.41%)
MSFT   283.20 (-3.73%)
FB   340.65 (-3.66%)
GOOGL   2,716.90 (-3.71%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   205.89 (-4.94%)
BABA   152.11 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.74 (-5.91%)
AMD   100.87 (-6.74%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.06 (-1.17%)
BA   218.41 (-2.57%)
AMC   36.68 (-6.67%)
NYSE:MED

Medifast Stock Forecast, Price & News

$201.68
-8.57 (-4.08 %)
(As of 09/28/2021 03:59 PM ET)
Add
Compare
Today's Range
$201.56
$207.21
50-Day Range
$203.68
$287.27
52-Week Range
$139.59
$336.99
Volume2,363 shs
Average Volume119,967 shs
Market Capitalization$2.37 billion
P/E Ratio15.89
Dividend Yield2.79%
Beta1.39
30 days | 90 days | 365 days | Advanced Chart
Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.


Medifast logo

About Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand-a highly competitive and effective lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
713
Year Founded
N/A

Sales & Book Value

Annual Sales
$934.84 million
Cash Flow
$8.51 per share
Book Value
$13.36 per share

Profitability

Net Income
$102.86 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.37 billion
Next Earnings Date
11/1/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

3.12 out of 5 stars

Consumer Staples Sector

4th out of 179 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 6 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 2.5Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Medifast (NYSE:MED) Frequently Asked Questions

Is Medifast a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast
or view top-rated stocks.

What stocks does MarketBeat like better than Medifast?

Wall Street analysts have given Medifast a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medifast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Medifast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Wednesday, August, 4th. The specialty retailer reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.30 by $0.66. The specialty retailer had revenue of $394.20 million for the quarter, compared to the consensus estimate of $359.25 million. Medifast had a net margin of 11.84% and a trailing twelve-month return on equity of 90.26%. The company's revenue for the quarter was up 79.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.86 EPS.
View Medifast's earnings history
.

How has Medifast's stock price been impacted by COVID-19?

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 188.0% and is now trading at $202.86.
View which stocks have been most impacted by COVID-19
.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, September 9th. Stockholders of record on Tuesday, September 21st will be given a dividend of $1.42 per share on Monday, November 8th. This represents a $5.68 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Monday, September 20th.
View Medifast's dividend history
.

Is Medifast a good dividend stock?

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 2.79%. Medifast does not yet have a strong track record of dividend growth. The dividend payout ratio of Medifast is 62.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 35.84% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided EPS guidance of $12.700-$14.170 for the period, compared to the Thomson Reuters consensus estimate of $13.800. The company issued revenue guidance of $1.43 billion-$1.53 billion, compared to the consensus revenue estimate of $1.46 billion.

What price target have analysts set for MED?

3 analysts have issued 12 month price targets for Medifast's shares. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's share price to reach $353.33 in the next year. This suggests a possible upside of 74.2% from the stock's current price.
View analysts' price targets for Medifast
or view top-rated stocks among Wall Street analysts.

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Daniel R. Chard, Executive Chairman & Chief Executive Officer
  • James P. Maloney, Chief Financial & Accounting Officer
  • William Baker, Executive Vice President-Information Technology
  • Jason L. Groves, Secretary, Executive VP & General Counsel
  • Nicholas M. Johnson, EVP-Coach Success & Market President

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.13%), Vanguard Group Inc. (12.29%), Renaissance Technologies LLC (7.63%), Dimensional Fund Advisors LP (3.24%), State Street Corp (3.16%) and Rice Hall James & Associates LLC (2.58%). Company insiders that own Medifast stock include Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast
.

Which institutional investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Millennium Management LLC, BlackRock Inc., Goldman Sachs Group Inc., Healthcare of Ontario Pension Plan Trust Fund, Bank of America Corp DE, JPMorgan Chase & Co., and Legal & General Group Plc. Company insiders that have sold Medifast company stock in the last year include Constance J Hallquist, Daniel R Chard, Kevin G Byrnes, Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast
or view top insider-selling stocks.

Which institutional investors are buying Medifast stock?

MED stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Allianz Asset Management GmbH, Epoch Investment Partners Inc., Vanguard Group Inc., Amundi, Geode Capital Management LLC, Prudential Financial Inc., and Skandinaviska Enskilda Banken AB publ.
View insider buying and selling activity for Medifast
or or view top insider-buying stocks.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $202.86.

How much money does Medifast make?

Medifast has a market capitalization of $2.38 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $9.14 on an earnings per share basis.

How many employees does Medifast have?

Medifast employs 713 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

Where are Medifast's headquarters?

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at (410) 581-8042 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.